Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
126.1 USD | -2.63% | -3.50% | +15.74% |
02:30pm | Merck: positive results for Keytruda in breast cancer | CF |
01:48pm | Merck Says Phase 3 Trial of Keytruda in Triple Negative Breast Cancer Met Overall Survival Endpoint | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.74% | 328B | |
+38.10% | 727B | |
-7.66% | 354B | |
-0.22% | 277B | |
+13.47% | 243B | |
+7.35% | 205B | |
-6.42% | 203B | |
+3.93% | 164B | |
-2.00% | 164B | |
-1.31% | 122B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Merck : Keytruda Trial Meets Primary Endpoint of Disease-Free Survival in Kidney Cancer